Despite evidence that genetic testing for prostate cancer improves clinical management, uptake remains low. Genetic testing identifies mutations in DNA repair genes like BRCA2, aiding personalized medicine and treatment decisions. Low testing rates impact eligibility for PARP inhibitors. Barriers include lack of genetic counselors, physician knowledge, and patient concerns. Studies show web-based tools and clinician-led counseling can increase testing rates. Timely testing is crucial for better outcomes, as HRR mutations correlate with worse prognosis. Genetic testing also influences prostate cancer grade classification and screening strategies, particularly for BRCA2 mutation carriers.